In women who are at an increased risk of inherited breast cancer and ovarian cancer, screening and prevention strategies can be instituted to reduce their risks, according to new clinical management guidelines from the American College of Obstetricians and Gynecologists (ACOG). The practice bulletin focuses on the primary genetic mutations associated with hereditary breast and ovarian cancer syndrome, BRCA1 and BRCA2, but also discusses some additional genes that have been implicated. Among the (Level B) recommendations:
- Genetic counseling is recommended for all women with ovarian epithelial cancer (this includes fallopian tube cancer or primary peritoneal cancer) and for individuals who have a personal or family history of breast cancer or ovarian cancer.
- Women with BRCA mutations or who carry another actionable deleterious mutation that is predisposing to breast cancer should be offered risk-reducing bilateral mastectomy.
- Women with BRCA mutations or who carry another actionable deleterious mutation predisposing to ovarian cancer should be offered risk-reducing bilateral salpingo-oophorectomy. The timing of risk-reducing bilateral salpingo-oophorectomy can be individualized based on the particular genetic mutation, the patient’s desires for future childbearing, and family history.
- For a risk-reducing bilateral salpingo-oophorectomy, all tissue from the ovaries and fallopian tubes should be removed.
Hereditary breast and ovarian cancer syndrome. Practice Bulletin No. 182. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2017:130:e110–26.
This Week's Must Reads
Low-Dose Aspirin Use During Pregnancy, Obstet Gynecol; ePub 2018 Jul; ACOG, SMFM
Postpartum Pain & Fatigue Management , Obstet Gynecol; ePub 2018 Jul; ACOG
Vaginal Preparation Before Cesarean Section, Cochrane Library; ePub 2018 Jul 17; Haas, et al
Maternal Outcomes by Race in Women Aged ≥40 Years, Obstet Gynecol; ePub 2018 Jul 10; Booker, et al
Orilissa Approved for Pain Management of Endometriosis, AbbVie news release; 2018 July 24
Must Reads in Breast Cancer
Estrogen-alone Therapy & Invasive Breast Cancer, Menopause; ePub 2018 May 7; Shufelt, et al
Missed Breast Cancers in High Risk MRI Screening, Breast Cancer Res Treat; ePub 2018 Jan 31; Vreemann, et al
FDA Approves Biosimilar for Certain Breast Cancers, FDA news release; 2017 Dec 1
Black-White Disparities in Breast Cancer Survival, J Clin Oncol; ePub 2017 Oct 16; Jemal, et al
Mammography Screening Patterns Evaluated, Womens Health Issues; ePub 2017 Sep 18; Jacobson, et al